Engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants. Researchers at the National Cancer Institute’s Laboratory of Molecular Biology have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suited for a variety of these functions. NCI seeks partners to license and/or co-develop this technology toward commercialization.
Researchers at the NCI developed immunologically active peptides of the human endogenous retrovirus ERVMER34-1 that bind to human leukocyte antigen A2 (HLA-A2) and elicit multifunctional T cell responses in cancer patients. These peptides and associated agonist epitopes can be used to develop cancer vaccines for the prevention and/or treatment of several cancer types. NCI seeks licensees or co-development partners to commercialize this invention.